Lexicon Pharmaceuticals, Inc. Share Price Nasdaq
Equities
US5288721047
Biotechnology & Medical Research
Sales 2024 * | 24.2M 2.02B | Sales 2025 * | 83.79M 7B | Capitalization | 441M 36.8B |
---|---|---|---|---|---|
Net income 2024 * | -200M -16.7B | Net income 2025 * | -201M -16.78B | EV / Sales 2024 * | 18.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.26 x |
P/E ratio 2024 * |
-2.34
x | P/E ratio 2025 * |
-2.61
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.71% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 07/14/07 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 01/99/01 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 02/21/02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01/01/01 |
Ray Debbane
CHM | Chairman | 69 | 01/07/01 |
Director/Board Member | 65 | 28/07/28 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |